# AlgenScribe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/algenscribe

- Industry: Biotechnology
- Headquarters: Nice, France
- Website: www.algenscribe.com
- Total disclosed funding: $0.6M
- Latest round: Seed (Nov 18, 2025)
- Investors on record: 2

## About

Based in France, AlgenScribe SAS specializes in genome editing solutions, focusing on developing advanced technologies to enhance genetic research and therapeutic applications. AlgenScribe SAS, founded in 2022, co-founded by CEO, Frédéric Zampatti, Dr. Isabelle Malcuit and Dr. Alexander Sorokin, operates out of Nice, France. The company is dedicated to genome editing innovations and has executed a total of one deal since its inception. On November 18, 2025, AlgenScribe successfully raised EUR 470,000 in Seed funding. AlgenScribe.com primarily provides domain registration services through its partnership with Gandi.net. The company helps a variety of clients, from individual entrepreneurs to established businesses, secure unique web addresses essential for branding and digital identity. Beyond domain registration, AlgenScribe offers insights into WHOIS data, enhancing clients' understanding of public registration details and domain ownership implications. The products cater to markets in North America, Europe, and Asia, addressing the needs of both startups and established firms seeking online branding solutions. AlgenScribe's revenue model is built on domain registration fees and related services for online presence management. Customers engage in transactions directly with the company, paying for domain registrations and renewals via subscription models. Fees vary by domain name extensions and additional services like WHOIS privacy protection. Clients may choose annual or multi-year registration plans, which provide cost savings while ensuring ownership of their domains. Specific pricing details are not publicly disclosed, but the revenue model is designed to serve a wide range of customers, from individuals to larger enterprises requiring multiple registrations. In November 2025, AlgenScribe raised EUR 470,000 in Seed funding from investors, Région Sud Investissement and Bpifrance. which will be allocated to further develop its genome-editing platform, including ex-vivo projects and early disease model studies. The company has plans to expand its market reach into new geographic areas, although specific regions and timelines are not mentioned. The recent funding is intended to bolster these initiatives and support the growth of AlgenScribe's innovative technologies.

## Funding rounds

- Seed, Nov 18, 2025, $0.6M — Bpifrance, Région Sud Investissement

## Investors

- Bpifrance — Seed
- Région Sud Investissement (https://capitalatlas.ai/funds/region-sud-investissement) — Seed